Business
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
Company to host conference call and webcast on Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc.
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\nCompany to host conference call and webcast on Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Tuesday, August 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.\n\n\nThe conference call will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until September 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.\n\n\nAbout Acadia Pharmaceuticals\n\n\nAcadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240724261503/en/\n\nInvestor Contact:\nAcadia Pharmaceuticals Inc.\nAl Kildani\n(858) 261-2872\[email protected]\n\n\nAcadia Pharmaceuticals Inc.\nJessica Tieszen\n(858) 261-2950\[email protected]\n\n\nSource: Acadia Pharmaceuticals Inc.","length":4517,"tagName":"div"}]